Publication

Opportunities for changes in the drug product design to enhance medication safety in older people: Evaluation of a national public portal for medication incidents

Karapinar-Çarkit, F., van den Bemt, P. M. L. A., Sadik, M., van Soest, B., Knol, W., van Hunsel, F. & van Riet-Nales, D. A., 2020, In : British Journal of Clinical Pharmacology. 86, 10, p. 1946-1957 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Opportunities for changes in the drug product design toenhance medication safety in older people Evaluation of anational public portal for medication incidents

    Final publisher's version, 6.63 MB, PDF document

    Request copy

DOI

AIMS: Medication safety requires urgent attention in hospital pharmacy. This study evaluated the medication-related problems/errors as reported to the Dutch medication incident registry and disseminated for information to pharmacists. Through analysis by an expert panel we aimed to better understand which problems could have been mitigated by the drug product design. Additionally, the (wider) implications of the problems for current hospital/clinical practice were discussed.

METHODS: Items were extracted from the public Portal for Patient Safety. Items were included if relevant for older people and connected with the drug product design and excluded if they should reasonably have been intercepted by compliance to routine controls or well-known professional standards in pharmaceutical care. To explore any underreporting of well-known incidents, it was investigated if different medication-related problems could be observed in a regional hospital practise over a 1-month period. For 6 included items (cases), the implications for hospital/clinical practise were discussed in an expert panel.

RESULTS: In total, 307 items were identified in the Portal for Patient Safety; all but 14 were excluded. Six cases were added from daily hospital practice. These 20 cases commonly related to confusing product characteristics, packaging issues such as the lack of a single unit package for an oncolytic product, or incorrect or incomplete user instructions.

CONCLUSION: Medication registries provide important opportunities to evaluate real-world medication-related problems. However, underreporting of well-known problems should be considered. The product design can be used as an (additional) risk mitigation measure to support medication safety in hospital practice.

Original languageEnglish
Pages (from-to)1946-1957
Number of pages12
JournalBritish Journal of Clinical Pharmacology
Volume86
Issue number10
Publication statusPublished - 2020

ID: 136271470